share_log

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

根諾西亞生物科學（NASDAQ：GNCA）覆蓋在 StockNews 上啟動
Financial News Live ·  2022/08/12 22:52

StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company's stock.

斯托克新聞網在週二發佈的一份研究報告中開始報道基因生物科學公司(納斯達克代碼：GNCA-GET Rating)的股票。該公司對這家生物技術公司的股票發佈了賣出評級。

A number of other equities analysts have also recently issued reports on GNCA. HC Wainwright cut Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th. Stifel Nicolaus cut Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. Finally, Robert W. Baird lowered their target price on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.

其他一些股票分析師最近也發佈了關於GNCA的報告。在4月29日星期五的一份報告中，HC Wainwright將Genocea Biosciences的評級從買入下調至中性。Stifel Nicolaus在4月29日星期五的一份報告中將Genocea Biosciences的評級從買入下調至持有。最後，羅伯特·W·貝爾德在4月11日星期一的一份報告中將Genocea Biosciences的目標價從8.00美元下調至3.00美元。

Get
到達
Genocea Biosciences
Genocea生物科學
alerts:
警報：

Genocea Biosciences Stock Performance

Genocea Bioscions股票表現

GNCA opened at $0.01 on Tuesday. The business has a fifty day moving average of $0.02 and a 200 day moving average of $0.50. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.

GNCA週二開盤報0.01美元。該業務的50日移動均線切入位在0.02美元，200日移動均線切入位在0.50美元。Genocea Biosciences的52周低點為0.01美元，52周高位為2.20美元。該公司的負債權益比率為0.24，速動比率為1.35，流動比率為1.35。

Insider Transactions at Genocea Biosciences

Genocea Biosciences的內幕交易

In related news, Director Ali Behbahani sold 4,445,093 shares of the company's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Ali Behbahani sold 4,445,093 shares of the company's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Paul Edward Walker sold 5,931,843 shares of the company's stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the transaction, the insider now directly owns 4,445,093 shares in the company, valued at $311,156.51. The disclosure for this sale can be found here. In the last three months, insiders sold 10,537,612 shares of company stock valued at $781,461. Corporate insiders own 1.61% of the company's stock.
在相關新聞中，董事Ali貝赫巴哈尼在一筆日期為5月25日(星期三)的交易中出售了4445,093股該公司股票。該股以0.08美元的平均價格出售，總成交金額為355,607.44美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的，可以通過以下鏈接訪問該檔案。在相關新聞中，董事Ali貝赫巴哈尼在一筆日期為5月25日(星期三)的交易中出售了4445,093股該公司股票。該股以0.08美元的平均價格出售，總成交金額為355,607.44美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的，可以通過以下鏈接訪問該檔案。此外，大股東保羅·愛德華·沃克在5月24日星期二的交易中出售了5931,843股公司股票。這些股票的平均價格為0.07美元，總價值為415,229.01美元。交易完成後，這位內部人士現在直接擁有該公司4,445,093股，價值311,156.51美元。此次拍賣的披露資訊可在此處找到。在過去的三個月裡，內部人士出售了10,537,612股公司股票，價值781,461美元。企業內部人士持有該公司1.61%的股份。

Institutional Inflows and Outflows

機構資金流入和流出

A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its position in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 59.25% of the company's stock.

一家對沖基金最近增持了Genocea Biosciences股票。根據不列顛國協股權服務公司提交給美國證券交易委員會的最新Form 13F檔案，該公司在Genocea Biosciences，Inc.(納斯達克代碼：GNCA-GET評級)的持倉在第四季度增長了49.4%。該公司持有這家生物技術公司31,981股股票，在此期間又購買了10,576股。截至最近一個季度末，不列顛國協股權服務公司擁有Genocea Biosciences公司約0.06%的股份，價值3.7萬美元。對沖基金和其他機構投資者持有該公司59.25%的股票。

About Genocea Biosciences

關於Genocea生物科學

(Get Rating)

(獲取評級)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Genocea Biosciences，Inc.是一家生物製藥公司，發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
  • 霍尼韋爾看好穩定和多元化的股票
  • 為什麼要投資高收益股利股票？
  • 找到並獲利於52周低點的股票交易
  • 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
  • 清潔能源法案通過後，太陽能股大放異彩

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論